 


NS5A :: Cocrystal Pharma, Inc. (COCP)






































































Home
Product Pipeline
NS5A











    Product Pipeline




CC-2069: A Pan-Genotypic Preclinical NS5A Inhibitor
CC-2069 is a novel highly potent, pan-genotypic, NS5A inhibitor that produces an active metabolite (also a pM HCV inhibitor).
CC-2069 is an excellent combination drug candidate with Nuc and/or NNI.
CC-2069 Activity Profile Against NS5A Drug Resistant Variants

Showed excellent potency against NS5A drug resistant variants
Showed acceptable cytotoxicity profile with high therapeutic index

CC-2069 Status

Preclinical characterization is ongoing
Phase 1 study scheduled for 2017






Viral Disease
Lead Discovery
Lead Optimization
Preclinical
Regulatory Filing
Phase 1





Hepatitis C	                CC-2069 (NS5A)	            


Lead Discovery Phase complete




Lead Optimization Phase complete




Preclinical Phase in progress




Regulatory Filing Phase not started




Phase 1 Phase not started














Sign Up for Email Alerts
Be the first to receive breaking news
Sign Up







 


Cocrystal Pharma, Inc. (COCP)





































































                    		Targeted Solutions for Viral Diseases                		
Using unprecedented knowledge of the antiviral nucleoside arena, Cocrystal Pharma’s therapies target high-mutating viral diseases such as Influenza, Hepatitis C, Norovirus and more.
View Product Pipeline











Technology
Our proprietary technologies enable the creation of first- and best-in-class antiviral products. Learn More




Development Programs
Our development programs include a wide variety of serious and/or chronic viral diseases such as Influenza and Hepatitis C. Learn More




About Us
Cocrystal Pharma uses proprietary and unique nucleoside chemistry combined with Nobel Prize winning expertise to target viral diseases. Learn More







Latest News



        			    June 01, 2017 •
        			
James J. Martin Appointed as Chief Financial Officer of Cocrystal Pharma, Inc.






Latest Media



        			    January 22, 2016 •
        			
Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration










        	Stock Data        	


View Investor Relations




OTCQB:
COCP



Change






Volume



Market Cap










Sign Up for Email Alerts
Be the first to receive breaking news
Sign Up







 


Contact Us :: Cocrystal Pharma, Inc. (COCP)






































































Home
Contact Us






Contact Us


Cocrystal Pharma, Inc.

Headquarters
            1860 Montreal Rd.
                		Tucker, GA 30084

 
19805 N. Creek ParkwayBothell, WA 98011 





First Name



Last Name



Email



Comments:


Submit



 







Sign Up for Email Alerts
Be the first to receive breaking news
Sign Up







 


Cocrystal Pharma, Inc. (COCP)





































































                    		Targeted Solutions for Viral Diseases                		
Using unprecedented knowledge of the antiviral nucleoside arena, Cocrystal Pharma’s therapies target high-mutating viral diseases such as Influenza, Hepatitis C, Norovirus and more.
View Product Pipeline











Technology
Our proprietary technologies enable the creation of first- and best-in-class antiviral products. Learn More




Development Programs
Our development programs include a wide variety of serious and/or chronic viral diseases such as Influenza and Hepatitis C. Learn More




About Us
Cocrystal Pharma uses proprietary and unique nucleoside chemistry combined with Nobel Prize winning expertise to target viral diseases. Learn More







Latest News



        			    June 01, 2017 •
        			
James J. Martin Appointed as Chief Financial Officer of Cocrystal Pharma, Inc.






Latest Media



        			    January 22, 2016 •
        			
Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration










        	Stock Data        	


View Investor Relations




OTCQB:
COCP



Change






Volume



Market Cap










Sign Up for Email Alerts
Be the first to receive breaking news
Sign Up







 


Overview :: Cocrystal Pharma, Inc. (COCP)






































































Home
Product Pipeline
Overview











    Product Pipeline




Cocrystal Product Pipeline
Targeting Viral Diseases with Pan-Genotypic Inhibitors
Our proprietary structural information, enzymology and nucleoside inhibitor expertise enable us to develop novel antiviral agents.
Viral Replication Enzymes are Clinically Proven Targets for Small Molecule Drugs
Replication enzymes are considered the Achilles heel of viruses and are essential for viral proliferation.
HCV Development: Three Different Classes of Drugs





Viral Disease
Lead Discovery
Lead Optimization
Preclinical
Regulatory Filing
Phase 1





Hepatitis C	                CC-31244 (NNI)	            


Lead Discovery Phase complete




Lead Optimization Phase complete




Preclinical Phase complete




Regulatory Filing Phase complete




Phase 1 Phase in progress





Hepatitis C	                CC-2850 (Nuc)	            


Lead Discovery Phase complete




Lead Optimization Phase complete




Preclinical Phase in progress




Regulatory Filing Phase not started




Phase 1 Phase not started





Hepatitis C	                CC-2069 (NS5A)	            


Lead Discovery Phase complete




Lead Optimization Phase complete




Preclinical Phase in progress




Regulatory Filing Phase not started




Phase 1 Phase not started





Influenza Inhibitor 


Lead Discovery Phase complete




Lead Optimization Phase in progress




Preclinical Phase not started




Regulatory Filing Phase not started




Phase 1 Phase not started





Norovirus	                (Nuc/non-Nuc)	            


Lead Discovery Phase complete




Lead Optimization Phase in progress




Preclinical Phase not started




Regulatory Filing Phase not started




Phase 1 Phase not started








CC-31244: A Pan-Genotypic Non-Nucleoside Inhibitor
The first-in-human study (Phase 1a/1b) to evaluate safety, antiviral activity and pharmacokinetics of CC-31244 was initiated in April, 2016 and currently ongoing.
View CC-31244


CC-2850: A Pan-Genotypic Nucleoside Prodrug
CC-2850 is currently undergoing pre-clinical studies.
View CC-2850


CC-2069: A Pan-Genotypic NS5A Inhibitor
CC-2069 is currently undergoing pre-clinical studies.
View CC-2069

 







Sign Up for Email Alerts
Be the first to receive breaking news
Sign Up







 


Overview :: Cocrystal Pharma, Inc. (COCP)






































































Home
Product Pipeline
Overview











    Product Pipeline




Cocrystal Product Pipeline
Targeting Viral Diseases with Pan-Genotypic Inhibitors
Our proprietary structural information, enzymology and nucleoside inhibitor expertise enable us to develop novel antiviral agents.
Viral Replication Enzymes are Clinically Proven Targets for Small Molecule Drugs
Replication enzymes are considered the Achilles heel of viruses and are essential for viral proliferation.
HCV Development: Three Different Classes of Drugs





Viral Disease
Lead Discovery
Lead Optimization
Preclinical
Regulatory Filing
Phase 1





Hepatitis C	                CC-31244 (NNI)	            


Lead Discovery Phase complete




Lead Optimization Phase complete




Preclinical Phase complete




Regulatory Filing Phase complete




Phase 1 Phase in progress





Hepatitis C	                CC-2850 (Nuc)	            


Lead Discovery Phase complete




Lead Optimization Phase complete




Preclinical Phase in progress




Regulatory Filing Phase not started




Phase 1 Phase not started





Hepatitis C	                CC-2069 (NS5A)	            


Lead Discovery Phase complete




Lead Optimization Phase complete




Preclinical Phase in progress




Regulatory Filing Phase not started




Phase 1 Phase not started





Influenza Inhibitor 


Lead Discovery Phase complete




Lead Optimization Phase in progress




Preclinical Phase not started




Regulatory Filing Phase not started




Phase 1 Phase not started





Norovirus	                (Nuc/non-Nuc)	            


Lead Discovery Phase complete




Lead Optimization Phase in progress




Preclinical Phase not started




Regulatory Filing Phase not started




Phase 1 Phase not started








CC-31244: A Pan-Genotypic Non-Nucleoside Inhibitor
The first-in-human study (Phase 1a/1b) to evaluate safety, antiviral activity and pharmacokinetics of CC-31244 was initiated in April, 2016 and currently ongoing.
View CC-31244


CC-2850: A Pan-Genotypic Nucleoside Prodrug
CC-2850 is currently undergoing pre-clinical studies.
View CC-2850


CC-2069: A Pan-Genotypic NS5A Inhibitor
CC-2069 is currently undergoing pre-clinical studies.
View CC-2069

 







Sign Up for Email Alerts
Be the first to receive breaking news
Sign Up







 






Email Alerts :: Cocrystal Pharma, Inc. (COCP)






































































Home
Investors
News / Events
Email Alerts











    Investors



Email Alerts
Tear Sheet
Contacts
RSS News Feed





Email Alerts
Please fill out the form below to receive company press releases via email when they occur.




First Name:



Last Name:



Email:



Contact Type:

Individual Investor
Analyst
Broker/Investment Advisor
Portfolio Manager
Banker/Financing Source
Press/Media
Consultant
Employee
Customer/Client
Student
Other






Email Alerts

Press Releases



                                All Press Releases
                          


SEC Filings



                All SEC Filings
            



                        Annual & Quarterly Reports
                  




                        Current Reports
                  




                        Insider Transactions
                  




                        Proxy Information
                  















We respect your privacy. We do not sell, rent, or loan any information to any third party. Any information you give us is held with the utmost care and security, and will be used only in ways to which you have consented.  










 


Posters :: Cocrystal Pharma, Inc. (COCP)






































































Home
News
Posters











    News




Posters






Preclinical characterization of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor for the treatment of chronic hepatitis C











Sign Up for Email Alerts
Be the first to receive breaking news
Sign Up







 






Overview :: Cocrystal Pharma, Inc. (COCP)






































































Home
Investors
Overview











    Investors



Email Alerts
Tear Sheet
Contacts
RSS News Feed





Overview












Latest News



James J. Martin Appointed as Chief Financial Officer of Cocrystal Pharma, Inc.
Jun 1, 2017

Read Press Release

 


Sign up for email alerts
Be the first to receive breaking news
Sign up today
 



Latest Financial Results





2016
Year End Results
Dec 31, 2016





 PDF
        

 HTML
            

Release



 PDF
 HTML

10-K Filing



 PDF
 HTML

10-K/A Filing




 HTML
    

Financials



 ZIP
 XLS
 HTML

XBRL
 

 






Stock Information





OTCQB:
COCP




Price





Change
 




Mkt Cap



Volume










52 week Low/High







Day Low/High









Company Overview


Cocrystal Pharma, Inc. is a pharmaceutical company with a mission to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal Pharma employs unique nucleoside chemistry and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies and our market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. 




Officers & Directors




                Executive Leadership            



                Board of Directors            











Gary Wilcox
Vice Chairman and Interim Chief Executive Officer




                                                            Gary Wilcox has over 35 years of experience in biotech companies including 14 years at Icos Corporation where he played a key role in the development of Cialis as the Executive Vice President of Operations and a member of the board of…                                                                View Full Bio








Sam Lee, Ph.D.
President




                                                            Sam Lee, Ph.D., has 20 years of anti-infective drug discovery research experience. Prior to Cocrystal, he managed anti-infective drug discovery projects for eight years at ICOS Corporation where he was responsible for incorporating protein…                                                                View Full Bio








James J. Martin
Chief Financial Officer




                                                            Mr. Martin has served as Chief Financial Officer of Non-Invasive Monitoring Systems, Inc. (OTCPink:NIMU) since January 2011. Since November 2016, he has served as Chief Financial Officer of Motus GI Holdings, Inc, a privately held medical…                                                                View Full Bio














Raymond F. Schinazi
Chairman




                                                            Raymond F. Schinazi, Ph.D. is the Frances Winship Walters Professor of Pediatrics, Director, Laboratory of Biochemical Pharmacology and Director, HIV Cure Scientific Working Group at Emory University. Dr. Schinazi's Laboratory of…                                                                View Full Bio








Gary Wilcox
Vice Chairman and Interim Chief Executive Officer




                                                            Gary Wilcox has over 35 years of experience in biotech companies including 14 years at Icos Corporation where he played a key role in the development of Cialis as the Executive Vice President of Operations and a member of the board of…                                                                View Full Bio








David S. Block
Director




                                                            David S. Block has served since 2007 as President and Chief Executive Officer of Gliknik Inc., a biopharmaceutical company which he founded to create new therapies for people living with cancer and immune disorders. From 1990 through its…                                                                View Full Bio








Phillip Frost
Director




                                                            Phillip Frost is the Chairman and CEO of Opko Health, Inc. (NYSE: OPK). Dr. Frost is the former Chairman of the Board of Teva Pharmaceuticals (NYSE: TEVA). In January 2006 Teva acquired IVAX Corporation. Dr. Frost had served as Chairman…                                                                View Full Bio








Jane Hsiao
Director




                                                            Jane Hsiao is Vice Chairman and Chief Technical Officer of Opko Health, Inc. She served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006, when Teva acquired IVAX. Dr. Hsiao served as IVAX's chief technical officer…                                                                View Full Bio








Steve Rubin
Director




                                                            Steve Rubin is Executive Vice President-Administration and a director of OPKO Health, Inc. Previously, he was Senior Vice President and General Counsel of IVAX. Prior to IVAX, Mr. Rubin was Senior Vice President and General Counsel of…                                                                View Full Bio







 













Cocrystal Pharma, Inc. - Product Pipeline Review - 2016































| Compare 
About Us | 
Contact Us






Home
Research Category
Publisher List
Custom Research
Cart
Compare



Research Category
User Guide
Policies
Contact Us
About us
Site Map







Home > Market Research Report  > Pharmaceutical > Pharmaceutical Companies > Pharma Info









Market Research Report
Cocrystal Pharma, Inc. - Product Pipeline Review - 2016



Published by
Global Markets Direct
Product code
347606


Published
June 30, 2016
Content info
44 Pages 


Price








USD 1500

PDF by E-mail (Single user license)





USD 3000

PDF by E-mail (Site license)





USD 4500

PDF by E-mail (Global license)
























Cocrystal Pharma, Inc. - Product Pipeline Review - 2016



Published: June 30, 2016
Content info: 44 Pages














Description

Summary
Global Markets Direct's, 'Cocrystal Pharma, Inc. - Product Pipeline Review - 2016', provides an overview of the Cocrystal Pharma, Inc.'s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Cocrystal Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope

 The report provides a snapshot of the pipeline therapeutic landscape of Cocrystal Pharma, Inc.
 The report provides overview of Cocrystal Pharma, Inc. including its business description, key facts, and locations and subsidiaries
 The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
 The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
 The report assesses Cocrystal Pharma, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
 The report features Cocrystal Pharma, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

 Evaluate Cocrystal Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
 Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
 Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 Identify and understand important and diverse types of therapeutics under development for Cocrystal Pharma, Inc.
 Identify potential new clients or partners in the target demographic
 Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
 Devise corrective measures for pipeline projects by understanding Cocrystal Pharma, Inc.'s pipeline depth and focus of pipeline therapeutics
 Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope




Table of Contents
Product Code: GMDHC08075CDB
Table of Contents

Table of Contents 

List of Tables 
List of Figures

Cocrystal Pharma, Inc. Snapshot 

Cocrystal Pharma, Inc. Overview 
Key Information 
Key Facts 

Cocrystal Pharma, Inc. - Research and Development Overview 

Key Therapeutic Areas 

Cocrystal Pharma, Inc. - Pipeline Review 

Pipeline Products by Stage of Development 
Pipeline Products - Monotherapy 
Pipeline Products - Out-Licensed Products 

Out-Licensed Products/Combination Treatment Modalities 


Cocrystal Pharma, Inc. - Pipeline Products Glance 

Cocrystal Pharma, Inc. - Clinical Stage Pipeline Products 

Phase I Products/Combination Treatment Modalities 

Cocrystal Pharma, Inc. - Early Stage Pipeline Products 

Preclinical Products/Combination Treatment Modalities 
Discovery Products/Combination Treatment Modalities 


Cocrystal Pharma, Inc. - Drug Profiles 

CC-31244 

Product Description 
Mechanism of Action 
R&D Progress

CC-1845 

Product Description 
Mechanism of Action 
R&D Progress

CC-2068 

Product Description 
Mechanism of Action 
R&D Progress

CC-2069 

Product Description 
Mechanism of Action 
R&D Progress

CDI-244 

Product Description 
Mechanism of Action 
R&D Progress

Gene Therapy for Hepatitis B and Human Papilloma Virus Infections 

Product Description 
Mechanism of Action 
R&D Progress

CC-31326 

Product Description 
Mechanism of Action 
R&D Progress

RS-1137 

Product Description 
Mechanism of Action 
R&D Progress

RS-1142 

Product Description 
Mechanism of Action 
R&D Progress

RS-1145 

Product Description 
Mechanism of Action 
R&D Progress

RS-930 

Product Description 
Mechanism of Action 
R&D Progress

RS-961 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecule for Hepatitis C 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecules to Inhibit PB2 for Influenza 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecules to Inhibit RNA Dependent RNA Polymerase for Norovirus Infections 

Product Description 
Mechanism of Action 
R&D Progress


Cocrystal Pharma, Inc. - Pipeline Analysis 

Cocrystal Pharma, Inc. - Pipeline Products by Target 
Cocrystal Pharma, Inc. - Pipeline Products by Route of Administration 
Cocrystal Pharma, Inc. - Pipeline Products by Molecule Type 
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action 

Cocrystal Pharma, Inc. - Recent Pipeline Updates 
Cocrystal Pharma, Inc. - Dormant Projects 
Cocrystal Pharma, Inc. - Locations And Subsidiaries 

Head Office 
Other Locations & Subsidiaries 

Appendix 

Methodology 
Coverage 
Secondary Research 
Primary Research 
Expert Panel Validation 
Contact Us 
Disclaimer 


List of Tables

Cocrystal Pharma, Inc., Key Information 
Cocrystal Pharma, Inc., Key Facts 
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 
Cocrystal Pharma, Inc. - Out-Licensed Products in Pipeline, 2016 
Cocrystal Pharma, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 
Cocrystal Pharma, Inc. - Phase I, 2016 
Cocrystal Pharma, Inc. - Preclinical, 2016 
Cocrystal Pharma, Inc. - Discovery, 2016 
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 
Cocrystal Pharma, Inc. - Recent Pipeline Updates, 2016 
Cocrystal Pharma, Inc. - Dormant Developmental Projects,2016 
Cocrystal Pharma, Inc., Other Locations 

List of Figures

Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 








Phone


Int'l: +1-860-674-8796
TollFree(US): +1-866-353-3335
Europe: +32-2-535-7543
Asia: +65-6223-2436


New for 2017 !

GII now purchases any market research reports from any publishers for you.  
			With noextra cost.
Contact us for more details.

FAQ


Delivery Time
User License
Payment Options
Compare Multiple Reports


RELATED REPORTS


Head And Neck Cancer - Pipeline Review, H1 2017 published: May 16, 2017
Alchemia Ltd - Product Pipeline Review - 2016 published: Dec 30, 2016
Array BioPharma Inc - Product Pipeline Review - 2016 published: Dec 30, 2016
Bionomics Ltd - Product Pipeline Review - 2016 published: Dec 30, 2016
Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016 published: Dec 30, 2016
CSL Ltd - Product Pipeline Review - 2016 published: Dec 30, 2016
Genervon Biopharmaceuticals LLC - Product Pipeline Review - 2016 published: Dec 30, 2016
Genethon SA - Product Pipeline Review - 2016 published: Dec 30, 2016
Hutchison MediPharma Ltd - Product Pipeline Review - 2016 published: Dec 30, 2016
Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016 published: Dec 30, 2016



 ▼


















About
Contact
User Guide
Policies
Site Map



© Copyright 1997-2017, Global Information, Inc. All rights reserved.




 






Quote :: Cocrystal Pharma, Inc. (COCP)






































































Home
Investors
Stock Data
Quote











    Investors



Email Alerts
Tear Sheet
Contacts
RSS News Feed





Quote




Detailed Stock Quote


Stock Charts


Historical Quotes





 Loading Data... 










Sign Up for Email Alerts
Be the first to receive breaking news
Sign Up











Cocrystal Pharma, Inc. - Product Pipeline Review - 2016 | Acute Market Reports













About Us
 Contact Us
 Sitemap














Home
Our Services

Market Research Reports
Business Consulting
Prolonge Business Leverages
Plan Your Own Research


Industry Reports

Country Reports
Press Release
Login
Register





 Home / Healthcare / Cocrystal Pharma, Inc. - Product Pipeline Review - 2016 


Cocrystal Pharma, Inc. - Product Pipeline Review - 2016
Published: Jun 2016 | No Of Pages: 44 | Published By: Global Markets Direct



Report Summary  
  Table of content  
  List Of Tables  
  List Of Figures  
  Request Sample




Cocrystal Pharma, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Directs, Cocrystal Pharma, Inc. - Product Pipeline Review - 2016, provides an overview of the Cocrystal Pharma, Inc.s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Cocrystal Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Cocrystal Pharma, Inc.
- The report provides overview of Cocrystal Pharma, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Cocrystal Pharma, Inc.s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Cocrystal Pharma, Inc.s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Cocrystal Pharma, Inc.s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cocrystal Pharma, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cocrystal Pharma, Inc.s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Cocrystal Pharma, Inc. Snapshot 6
Cocrystal Pharma, Inc. Overview 6
Key Information 6
Key Facts 6
Cocrystal Pharma, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Cocrystal Pharma, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Cocrystal Pharma, Inc. - Pipeline Products Glance 14
Cocrystal Pharma, Inc. - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Cocrystal Pharma, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Cocrystal Pharma, Inc. - Drug Profiles 17
CC-31244 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CC-1845 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CC-2068 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CC-2069 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CDI-244 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy for Hepatitis B and Human Papilloma Virus Infections 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CC-31326 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RS-1137 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
RS-1142 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RS-1145 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RS-930 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RS-961 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Hepatitis C 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit PB2 for Influenza 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Norovirus Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cocrystal Pharma, Inc. - Pipeline Analysis 34
Cocrystal Pharma, Inc. - Pipeline Products by Target 34
Cocrystal Pharma, Inc. - Pipeline Products by Route of Administration 35
Cocrystal Pharma, Inc. - Pipeline Products by Molecule Type 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates 38
Cocrystal Pharma, Inc. - Dormant Projects 41
Cocrystal Pharma, Inc. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44 

Cocrystal Pharma, Inc., Key Information 6
Cocrystal Pharma, Inc., Key Facts 6
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc. - Out-Licensed Products in Pipeline, 2016 12
Cocrystal Pharma, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Cocrystal Pharma, Inc. - Phase I, 2016 14
Cocrystal Pharma, Inc. - Preclinical, 2016 15
Cocrystal Pharma, Inc. - Discovery, 2016 16
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 34
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates, 2016 38
Cocrystal Pharma, Inc. - Dormant Developmental Projects,2016 41
Cocrystal Pharma, Inc., Other Locations 42 
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 34
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 37  



Choose License Type 



Single User - $1500
Multi User - $3000
Enterprise - $4500


Buy Now
 



Contact Information 

 24/7 Research Support
 Phone: +1-855-455-8662 
 sales@acutemarketreports.com



Get in Touch with us 

 join us on Facebook
 Follow us on Twitter
 Follow us on LinkedIn
 Add us on Google +








Home
 About Us
 Customer Faq
 How to order
 Privacy Policy
 Terms of use



© Copyright 2017 Acute Market Reports
        and its Affiliates. All Rights Reserved
     


Newsletter Sign Up
      Signup for latest updates & promos
      

SEND

Payment Options:
 

Contact us
  ACUTE MARKET REPORTS
        Office No 01, 1st Floor , 
        Aditi Mall, Baner, 
		Pune, MH, 411045 
		India
  Toll Free(US/CANADA): +1-855-455-8662  India: +91 7755981103 
  sales@acutemarketreports.com 







































| FiercePharma

































Skip to main content

































Twitter
LinkedIn




Search


































 







- Any -ebookeBriefeventexecutive summaryjobmultimediapaid marketplaceresearchsurveyvideowebinarwhitepaper


- Any ---homepage--Pharma-M&A-Regulatory-Financials-Corporate-LegalManufacturing-M&A-Outsourcing-Regulatory-Supply Chain-Drug Safety-PartneringMarketing-Regulatory-DTC Advertising-Digital and Social Media-Data and Analytics-LaunchesPharma Asia-M&A-Manufacturing-R&D-Regulatory-Sales and Marketing-FinancialsAnimal Health-M&A-R&D-Regulatory-Veterinarian-Financials-VaccinesDrug Delivery-R&D-Regulatory-PartneringVaccines-Deals-Infectious Diseases-R&D-Regulatory


Sort by
Published Date


Order
OldestNewest





  



webinarExploring ADC Pharmacokinetics Using QSP Modeling StrategiesSeptember 13, 2017 | 2pm ET / 11am PT | Presented By Applied BioMath The Pharmacokinetics (PK) of ADC therapeutics typically show a discrepancy between the PK of total antibody and that of conjugated antibody, carrying one or more payload molecules. This will present how quantitative systems pharmacology modeling approaches provide biological insights into the impact of drug-to-antibody ratio and the resulting changes in molecular properties on overall PK and relative payload disposition as observed in preclinical and clinical studies. Register now!
More Info


  



webinar Small Size, Big Plans – Product Development Advice for Small CompaniesAugust 21, 2017 | 1pm ET/10am PT | Presented By Rho This webinar will provide advice on how to set your small company up for long-term success through the use of strategic development plans, purposeful outsourcing, patent protection, partnership strategies, and provide specific examples of success stories and lessons learned. Register now!
More Info


  



webinarMagnify Customer Engagement Productivity with Unified, Cognitive Search on Salesforce Service CloudAugust 10, 2017 | 2pm ET / 11am PT | Presented By Persistent Systems Obtain greater productivity and effectiveness in the matters of patient and member engagement! This webinar will present the packaged solution that enables single window, proactive access within the Salesforce Service Console for customer service representatives & supervisors to effectively manage their patient and member populations. Register Now!
More Info


  



webinarAccelerate Clinical Trials with Rapid Application DevelopmentAugust 9, 2017 | 2 pm ET / 11 am PT | Presented By Salesforce Clinical trials are at a crossroads. Biopharmaceutical companies must accelerate the development and approval of tailored therapeutics, but legacy clinical IT infrastructure makes it difficult to keep up. This webinar will highlight how life science companies are building connected R&D applications using an agile, intelligent platform that connects key stakeholders, including sponsors, CROs, sites, and subjects. Learn from customer success stories and live demonstrations, and see how you can apply this approach to turbocharge your own clinical programs. Register now.
More Info


  



webinarBring Your Life Sciences Content Management Strategy into the Digital AgeAugust 2, 2017 | 12pm ET / 9am PT | Presented By Medidata Solutions The life sciences industry is undergoing a digital transformation, as legacy IT systems move into the cloud and cohesive transition strategies are required. Whether you’re in Quality Control, Clinical Operations, IT, Regulatory Compliance, or manage another area of the trial, join Medidata and Box explore how to build a total regulated and non-regulated content management strategy to match today's unique challenges, including implementing technology via a single, user-friendly platform. Register now!
More Info


  



webinarImplementing a Common Data Model in a Real-World Analytics EnvironmentSponsored By Evidera This webinar “Implementing a Common Data Model (CDM) in a Real-World Informatics and Analytics Environment: Headwinds or Smooth Sailing?” explores CDM research vs practice and the issues encountered when implementing a CDM in practice, including alternative approaches and potential best practices. Watch now.
More Info


  



whitepaperReal-World Evidence in Payer Negotiations – What’s in Your Playbook?Sponsored By Evidera Real-World Evidence plays an important role in acquiring and defending optimal payer position. Read our white paper on the use of RWE to align with payers on environment & value vs. competitors at launch, defend payer positioning, and potentially bolster and extend the value of on-market products.
More Info


  



webinarConnecting the Drug Development Journey with Data-Driven InsightsJuly 27, 2017 | 11am ET / 8am PT | Presented By PAREXEL 
While biopharmaceutical companies face challenges in generating and integrating meaningful insights that drive timely and actionable decisions. Aggregating and leveraging the right data to drive value requires a broad range of services working together to generate insights across the entire drug development spectrum. Hear PAREXEL experts derive data-driven insights and how these insights can benefit many essential drug development areas. Register now!
More Info


  



webinarHow Modern Quality Systems are Transforming Change ManagementJuly 27, 2017 | 2pm ET / 11am PT | Presented By Veeva Assessing impact, and creating and executing a change plan are difficult with global stakeholders and multitude of systems. During this webinar, learn frameworks and best practices for transforming change management. Register Now!
More Info


  



webinarAccelerate Your Speed to Market: New Options  for Generic Drug Packaging & DeliveryNow Available On-Demand | Presented By West Pharmaceutical Services Quality. Speed. Simplicity. Learn how a new elastomeric closure formulation, turnkey extractables and leachables package and a flexible supply can help generics manufacturers make the move to market. Join this webinar with West experts and learn about generics market trends and AccelTRA™ brand program attributes that address generic injectable drug manufacturer issues and ensure a fast move to market. Register now!
More Info



























Popular Content 

AstraZeneca's Mystic shortfall is an immuno-oncology shake-up for Bristol-Myers and a bolster for Merck and Roche 
      		
      		Jul 27, 2017 
     		
New GlaxoSmithKline chief Walmsley makes early mark with sweeping pharma overhaul 
      		
      		Jul 26, 2017 
     		
AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B 
      		
      		Jul 27, 2017 
     		
Roche’s deep discount for MS drug Ocrevus pays off big for Swiss drugmaker 
      		
      		Jul 27, 2017 
     		
Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals 
      		
      		Jul 26, 2017 
     		





























































| FiercePharma

































Skip to main content

































Twitter
LinkedIn




Search


































 







- Any ---homepage--Pharma-M&A-Regulatory-Financials-Corporate-LegalManufacturing-M&A-Outsourcing-Regulatory-Supply Chain-Drug Safety-PartneringMarketing-Regulatory-DTC Advertising-Digital and Social Media-Data and Analytics-LaunchesPharma Asia-M&A-Manufacturing-R&D-Regulatory-Sales and Marketing-FinancialsAnimal Health-M&A-R&D-Regulatory-Veterinarian-Financials-VaccinesDrug Delivery-R&D-Regulatory-PartneringVaccines-Deals-Infectious Diseases-R&D-Regulatory


Sort by
Published Date


Order
OldestNewest





  



eventFierceBiotech 2nd Drug Development ForumSeptember 25-27, 2017 | Boston, MA | Sponsored By FierceBiotech Join 350+ c-suite biotech executives at the unmatched educational venue for drug development professionals. This event will cover the greatest partnership challenges that biotech companies face throughout the entire product and corporate development cycle! To learn more or register click here.
More Info


























Popular Content 

AstraZeneca's Mystic shortfall is an immuno-oncology shake-up for Bristol-Myers and a bolster for Merck and Roche 
      		
      		Jul 27, 2017 
     		
New GlaxoSmithKline chief Walmsley makes early mark with sweeping pharma overhaul 
      		
      		Jul 26, 2017 
     		
AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B 
      		
      		Jul 27, 2017 
     		
Roche’s deep discount for MS drug Ocrevus pays off big for Swiss drugmaker 
      		
      		Jul 27, 2017 
     		
Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals 
      		
      		Jul 26, 2017 
     		










































Bing Places for Business
























































































































Bing
 places for business


Sign in using your




Microsoft Account





Work Account





Google Account





Facebook Account

Don't have an account? Create one.







Cocrystal Pharma, Inc. - Product Pipeline Review - 2016 : Market Reports Center


























 info@marketreportscenter.com
 +1-646-883-3044 (US) 24x7















LOGIN
SIGN UP














Facebook



Twitter



LinkedIn



Google +



MRC Blog



YouTube







Cocrystal Pharma, Inc. - Product Pipeline Review - 2016

Home >> Pharmaceuticals >> Global Markets Direct >> Cocrystal Pharma, Inc. - Product Pipeline Review - 2016



Report Details





Cocrystal Pharma, Inc. - Product Pipeline Review - 2016







SKU
GMDAUG051607


Category
Pharmaceuticals


Publisher
Global Markets Direct


Pages
44


Published
Jun-16





SKUGMDAUG051607
CategoryPharmaceuticals
PublisherGlobal Markets Direct
Pages44
Published OnJun-16

Request Discount
Pay by Wire/Invoice





Description
Table of Content
List of Figures
Request Sample




Description
Cocrystal Pharma, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Directs, Cocrystal Pharma, Inc. - Product Pipeline Review - 2016, provides an overview of the Cocrystal Pharma, Inc.s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Cocrystal Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Cocrystal Pharma, Inc.
- The report provides overview of Cocrystal Pharma, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Cocrystal Pharma, Inc.s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Cocrystal Pharma, Inc.s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Cocrystal Pharma, Inc.s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cocrystal Pharma, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cocrystal Pharma, Inc.s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

News/Press Release

Precision Medicine: How the life science industry can improve outcomes through To achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option, researchers in drug R&D need to better understand and manage the reams of unstructured dat...Read More
Regenerative Medicine Market to Hit $53 billion by 2021 The current regenerative medicine market is worth $18.9 billion globally, and will hit over $53 billion by 2021, as impact of Trump administration....Read More
7 Benefits of MicroneedlingMicroneedling: Hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your face....Read More



Table of Content
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Cocrystal Pharma, Inc. Snapshot 6
Cocrystal Pharma, Inc. Overview 6
Key Information 6
Key Facts 6
Cocrystal Pharma, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Cocrystal Pharma, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Cocrystal Pharma, Inc. - Pipeline Products Glance 14
Cocrystal Pharma, Inc. - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Cocrystal Pharma, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Cocrystal Pharma, Inc. - Drug Profiles 17
CC-31244 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CC-1845 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CC-2068 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CC-2069 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CDI-244 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy for Hepatitis B and Human Papilloma Virus Infections 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CC-31326 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RS-1137 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
RS-1142 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RS-1145 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RS-930 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RS-961 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Hepatitis C 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit PB2 for Influenza 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Norovirus Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cocrystal Pharma, Inc. - Pipeline Analysis 34
Cocrystal Pharma, Inc. - Pipeline Products by Target 34
Cocrystal Pharma, Inc. - Pipeline Products by Route of Administration 35
Cocrystal Pharma, Inc. - Pipeline Products by Molecule Type 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates 38
Cocrystal Pharma, Inc. - Dormant Projects 41
Cocrystal Pharma, Inc. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44


List of Figures
List of Tables
Cocrystal Pharma, Inc., Key Information 6
Cocrystal Pharma, Inc., Key Facts 6
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc. - Out-Licensed Products in Pipeline, 2016 12
Cocrystal Pharma, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Cocrystal Pharma, Inc. - Phase I, 2016 14
Cocrystal Pharma, Inc. - Preclinical, 2016 15
Cocrystal Pharma, Inc. - Discovery, 2016 16
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 34
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates, 2016 38
Cocrystal Pharma, Inc. - Dormant Developmental Projects,2016 41
Cocrystal Pharma, Inc., Other Locations 42
List of Figures
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 34
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 37







Please Select License Type






Single User Electronic PDF 
$ 1,500.00


Site User Electronic PDF 
$ 3,000.00


Enterprise Wide Electronic PDF 
$ 4,500.00



ADD TO CART

BUY NOW






Related Reports




 Global Incoloy Alloy MA 956 Sales Market Report 2017 Global Zinc Dimethyldithiocarbamate Market Research Report 2017 Global Grate Bars for Refuse Incinerators Industry Report 2012-2022 Global and Chinese zinc trifluoromethanesulphonate (CAS 54010-75-2) Industry, 2017 Market Research Report Global and Chinese Zinc Fumarate (CAS 52723-61-2) Industry, 2017 Market Research Report 










Request Sample






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Request Discount






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Pay by Wire/Invoice






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
















Single User Electronic PDF
Site User Electronic PDF
Enterprise Wide Electronic PDF
CD ROM
Hard Copy














SEND










Request Quote






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND









Market Reports Center © Copyright 2017 All rights reserved.










































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft











Cocrystal Pharma, Inc. - Product Pipeline Review - 2016









































Home
Publishers
Latest Reports
Company Reports




Welcome! Login or Create an account











 The Market Reports 








Call: +1-631-407-1315 / +91-750-729-1479 Email: sales@themarketreports.com











 



Cocrystal Pharma, Inc. - Product Pipeline Review - 2016










  Email to a Friend






Cocrystal Pharma, Inc. - Product Pipeline Review - 2016


Publishing Date : Jun, 2016 


License Type :


Single User Price US$ 1,500.00
Site Price US$ 3,000.00
Enterprise Price US$ 4,500.00






+ Buy Now





Report Code : 180278

No of Pages : 44
+ Ask Your Query






Report Description
Table of Content


SynopsisThe report provides comprehensive information on the therapeutics under development by Cocrystal Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.SummaryGlobal Markets Direct’s, ‘Cocrystal Pharma, Inc. - Product Pipeline Review - 2016’, provides an overview of the Cocrystal Pharma, Inc.’s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Cocrystal Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.Scope- The report provides a snapshot of the pipeline therapeutic landscape of Cocrystal Pharma, Inc.
- The report provides overview of Cocrystal Pharma, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Cocrystal Pharma, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Cocrystal Pharma, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projectsReasons To Buy- Evaluate Cocrystal Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cocrystal Pharma, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cocrystal Pharma, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeGeographical AreaGlobal
IndexTable of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Cocrystal Pharma, Inc. Snapshot 6
Cocrystal Pharma, Inc. Overview 6
Key Information 6
Key Facts 6
Cocrystal Pharma, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Cocrystal Pharma, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Cocrystal Pharma, Inc. - Pipeline Products Glance 14
Cocrystal Pharma, Inc. - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Cocrystal Pharma, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Cocrystal Pharma, Inc. - Drug Profiles 17
CC-31244 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CC-1845 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CC-2068 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CC-2069 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CDI-244 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy for Hepatitis B and Human Papilloma Virus Infections 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CC-31326 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RS-1137 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
RS-1142 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RS-1145 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RS-930 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RS-961 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Hepatitis C 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit PB2 for Influenza 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Norovirus Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cocrystal Pharma, Inc. - Pipeline Analysis 34
Cocrystal Pharma, Inc. - Pipeline Products by Target 34
Cocrystal Pharma, Inc. - Pipeline Products by Route of Administration 35
Cocrystal Pharma, Inc. - Pipeline Products by Molecule Type 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates 38
Cocrystal Pharma, Inc. - Dormant Projects 41
Cocrystal Pharma, Inc. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44List of TablesList of Tables
Cocrystal Pharma, Inc., Key Information 6
Cocrystal Pharma, Inc., Key Facts 6
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc. - Out-Licensed Products in Pipeline, 2016 12
Cocrystal Pharma, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Cocrystal Pharma, Inc. - Phase I, 2016 14
Cocrystal Pharma, Inc. - Preclinical, 2016 15
Cocrystal Pharma, Inc. - Discovery, 2016 16
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 34
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates, 2016 38
Cocrystal Pharma, Inc. - Dormant Developmental Projects,2016 41
Cocrystal Pharma, Inc., Other Locations 42List of FiguresList of Figures
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 34
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 37






Published By : Global Markets Direct









Search by

Category

AutomotiveChemicalsEnergy & PowerFinancialFood & BeveragesIndustrialIT & ElectronicsLife SciencePublic SectorRetail 
Price

Below $1000
$1001 to $2500
$2501 to $5000
$5001 to $10000
$10001 to $20000
$20001 & Above







Latest Pharmaceuticals and Healthcare  Market Reports 

Pernix Therapeutics Holdings Inc (PTX) - Financial and Strategic SWOT Analysis Review

Synergy Pharmaceuticals Inc (SGYP) - Financial and Strategic SWOT Analysis Review

Eurofins Scientific SE (ERF) - Financial and Strategic SWOT Analysis Review

Bachem Holding AG (BANB) - Financial and Strategic SWOT Analysis Review

Navamedic ASA (NAVA) - Financial and Strategic SWOT Analysis Review
 










About Us
Terms & Conditions
Contact Us








Payments Accepted From 















Connect with us at



















Complete Secure Website


































































Cocrystal Pharma, Inc. - Product Pipeline Review - 2016 Trends, Statistics, Segment and Forecasts, Market Size, Share Analysis : Market Research Store



















+49 322 210 92714
                                    (GMT OFFICE HOURS)
                                

+1-855-465-4651
                                    (US/CAN TOLL FREE)
                                

+1-386-310-3803
                                    (US OFFICE NO)
                                
































Home
Categories
Become Publisher
News
About Us
Contact Us



























-Select Category-
Consumer Goods
Food & Beverage
Heavy Industry
Life Sciences
Marketing & Market Research
Public Sector
Service Industries
Technology & Media
Semiconductor
Chemical and Materials
Metallurgical
Market Research




Search












Home >> Life Sciences >> Pharmaceuticals


Cocrystal Pharma, Inc. - Product Pipeline Review - 2016



Published: Jun-2016 | Format: PDF | Global Markets Direct | Number of pages: 44 | Code: MRS - 69528



Report Details
Table Of Content
Inquiry For Buying
Request Sample



Cocrystal Pharma, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Cocrystal Pharma, Inc. - Product Pipeline Review - 2016’, provides an overview of the Cocrystal Pharma, Inc.’s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Cocrystal Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Cocrystal Pharma, Inc.
- The report provides overview of Cocrystal Pharma, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Cocrystal Pharma, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Cocrystal Pharma, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Cocrystal Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cocrystal Pharma, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cocrystal Pharma, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Cocrystal Pharma, Inc. Snapshot 6
Cocrystal Pharma, Inc. Overview 6
Key Information 6
Key Facts 6
Cocrystal Pharma, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Cocrystal Pharma, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Cocrystal Pharma, Inc. - Pipeline Products Glance 14
Cocrystal Pharma, Inc. - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Cocrystal Pharma, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Cocrystal Pharma, Inc. - Drug Profiles 17
CC-31244 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CC-1845 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CC-2068 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CC-2069 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CDI-244 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy for Hepatitis B and Human Papilloma Virus Infections 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CC-31326 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RS-1137 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
RS-1142 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RS-1145 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RS-930 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RS-961 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Hepatitis C 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit PB2 for Influenza 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Norovirus Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cocrystal Pharma, Inc. - Pipeline Analysis 34
Cocrystal Pharma, Inc. - Pipeline Products by Target 34
Cocrystal Pharma, Inc. - Pipeline Products by Route of Administration 35
Cocrystal Pharma, Inc. - Pipeline Products by Molecule Type 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates 38
Cocrystal Pharma, Inc. - Dormant Projects 41
Cocrystal Pharma, Inc. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44 
List of Tables
Cocrystal Pharma, Inc., Key Information 6
Cocrystal Pharma, Inc., Key Facts 6
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc. - Out-Licensed Products in Pipeline, 2016 12
Cocrystal Pharma, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Cocrystal Pharma, Inc. - Phase I, 2016 14
Cocrystal Pharma, Inc. - Preclinical, 2016 15
Cocrystal Pharma, Inc. - Discovery, 2016 16
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 34
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates, 2016 38
Cocrystal Pharma, Inc. - Dormant Developmental Projects,2016 41
Cocrystal Pharma, Inc., Other Locations 42 
List of Figures
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 34
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 37 

Inquiry For Buying

Please fill your details below, to inquire about this report:
* Indicates required fields






 





Name:






Email:






Phone:






Name of company:






Title/Designation:






Country Name:

-Select Country-
ANDORRA
UNITED ARAB EMIRATES
AFGHANISTAN
ANTIGUA AND BARBUDA
ANGUILLA
ALBANIA
ARMENIA
ANGOLA
ANTARCTICA
ARGENTINA
AMERICAN SAMOA
AUSTRIA
AUSTRALIA
ARUBA
ÅLAND ISLANDS
AZERBAIJAN
BOSNIA AND HERZEGOVINA
BARBADOS
BANGLADESH
BELGIUM
BURKINA FASO
BULGARIA
BAHRAIN
BURUNDI
BENIN
SAINT BARTHÉLEMY
BERMUDA
BRUNEI DARUSSALAM
BOLIVIA, PLURINATIONAL STATE OF
BONAIRE, SINT EUSTATIUS AND SABA
BRAZIL
BAHAMAS
BHUTAN
BOUVET ISLAND
BOTSWANA
BELARUS
BELIZE
CANADA
COCOS (KEELING) ISLANDS
CONGO, THE DEMOCRATIC REPUBLIC OF THE
CENTRAL AFRICAN REPUBLIC
CONGO
SWITZERLAND
CÔTE D'IVOIRE
COOK ISLANDS
CHILE
CAMEROON
CHINA
COLOMBIA
COSTA RICA
CUBA
CAPE VERDE
CURAÇAO
CHRISTMAS ISLAND
CYPRUS
CZECH REPUBLIC
GERMANY
DJIBOUTI
DENMARK
DOMINICA
DOMINICAN REPUBLIC
ALGERIA
ECUADOR
ESTONIA
EGYPT
WESTERN SAHARA
ERITREA
SPAIN
ETHIOPIA
FINLAND
FIJI
FALKLAND ISLANDS (MALVINAS)
MICRONESIA, FEDERATED STATES OF
FAROE ISLANDS
FRANCE
GABON
UNITED KINGDOM
GRENADA
GEORGIA
FRENCH GUIANA
GUERNSEY
GHANA
GIBRALTAR
GREENLAND
GAMBIA
GUINEA
GUADELOUPE
EQUATORIAL GUINEA
GREECE
SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS
GUATEMALA
GUAM
GUINEA-BISSAU
GUYANA
HONG KONG
HEARD ISLAND AND MCDONALD ISLANDS
HONDURAS
CROATIA
HAITI
HUNGARY
INDONESIA
IRELAND
ISRAEL
ISLE OF MAN
INDIA
BRITISH INDIAN OCEAN TERRITORY
IRAQ
IRAN, ISLAMIC REPUBLIC OF
ICELAND
ITALY
JERSEY
JAMAICA
JORDAN
JAPAN
KENYA
KYRGYZSTAN
CAMBODIA
KIRIBATI
COMOROS
SAINT KITTS AND NEVIS
KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF
KOREA, REPUBLIC OF
KUWAIT
CAYMAN ISLANDS
KAZAKHSTAN
LAO PEOPLE'S DEMOCRATIC REPUBLIC
LEBANON
SAINT LUCIA
LIECHTENSTEIN
SRI LANKA
LIBERIA
LESOTHO
LITHUANIA
LUXEMBOURG
LATVIA
LIBYA
MOROCCO
MONACO
MOLDOVA, REPUBLIC OF
MONTENEGRO
SAINT MARTIN (FRENCH PART)
MADAGASCAR
MARSHALL ISLANDS
MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF
MALI
MYANMAR
MONGOLIA
MACAO
NORTHERN MARIANA ISLANDS
MARTINIQUE
MAURITANIA
MONTSERRAT
MALTA
MAURITIUS
MALDIVES
MALAWI
MEXICO
MALAYSIA
MOZAMBIQUE
NAMIBIA
NEW CALEDONIA
NIGER
NORFOLK ISLAND
NIGERIA
NICARAGUA
NETHERLANDS
NORWAY
NEPAL
NAURU
NIUE
NEW ZEALAND
OMAN
PANAMA
PERU
FRENCH POLYNESIA
PAPUA NEW GUINEA
PHILIPPINES
PAKISTAN
POLAND
SAINT PIERRE AND MIQUELON
PITCAIRN
PUERTO RICO
PALESTINIAN, STATE OF
PORTUGAL
PALAU
PARAGUAY
QATAR
RÉUNION
ROMANIA
SERBIA
RUSSIAN FEDERATION
RWANDA
SAUDI ARABIA
SOLOMON ISLANDS
SEYCHELLES
SUDAN
SWEDEN
SINGAPORE
SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA
SLOVENIA
SVALBARD AND JAN MAYEN
SLOVAKIA
SIERRA LEONE
SAN MARINO
SENEGAL
SOMALIA
SURINAME
SOUTH SUDAN
SAO TOME AND PRINCIPE
EL SALVADOR
SINT MAARTEN (DUTCH PART)
SYRIAN ARAB REPUBLIC
SWAZILAND
TURKS AND CAICOS ISLANDS
CHAD
FRENCH SOUTHERN TERRITORIES
TOGO
THAILAND
TAJIKISTAN
TOKELAU
TIMOR-LESTE
TURKMENISTAN
TUNISIA
TONGA
TURKEY
TRINIDAD AND TOBAGO
TUVALU
TAIWAN, PROVINCE OF CHINA
TANZANIA, UNITED REPUBLIC OF
UKRAINE
UGANDA
UNITED STATES MINOR OUTLYING ISLANDS
UNITED STATES
URUGUAY
UZBEKISTAN
HOLY SEE (VATICAN CITY STATE)
SAINT VINCENT AND THE GRENADINES
VENEZUELA, BOLIVARIAN REPUBLIC OF
VIRGIN ISLANDS, BRITISH
VIRGIN ISLANDS, U.S.
VIET NAM
VANUATU
WALLIS AND FUTUNA
SAMOA
YEMEN
MAYOTTE
SOUTH AFRICA
ZAMBIA
ZIMBABWE





How can we help you?











Refresh



captcha:





 


Submit







Request Sample

Please fill your details below, to receive sample report:
* Indicates required fields






 





Name:






Email:






Phone:






Name of company:






Title/Designation:






Country Name:

-Select Country-
ANDORRA
UNITED ARAB EMIRATES
AFGHANISTAN
ANTIGUA AND BARBUDA
ANGUILLA
ALBANIA
ARMENIA
ANGOLA
ANTARCTICA
ARGENTINA
AMERICAN SAMOA
AUSTRIA
AUSTRALIA
ARUBA
ÅLAND ISLANDS
AZERBAIJAN
BOSNIA AND HERZEGOVINA
BARBADOS
BANGLADESH
BELGIUM
BURKINA FASO
BULGARIA
BAHRAIN
BURUNDI
BENIN
SAINT BARTHÉLEMY
BERMUDA
BRUNEI DARUSSALAM
BOLIVIA, PLURINATIONAL STATE OF
BONAIRE, SINT EUSTATIUS AND SABA
BRAZIL
BAHAMAS
BHUTAN
BOUVET ISLAND
BOTSWANA
BELARUS
BELIZE
CANADA
COCOS (KEELING) ISLANDS
CONGO, THE DEMOCRATIC REPUBLIC OF THE
CENTRAL AFRICAN REPUBLIC
CONGO
SWITZERLAND
CÔTE D'IVOIRE
COOK ISLANDS
CHILE
CAMEROON
CHINA
COLOMBIA
COSTA RICA
CUBA
CAPE VERDE
CURAÇAO
CHRISTMAS ISLAND
CYPRUS
CZECH REPUBLIC
GERMANY
DJIBOUTI
DENMARK
DOMINICA
DOMINICAN REPUBLIC
ALGERIA
ECUADOR
ESTONIA
EGYPT
WESTERN SAHARA
ERITREA
SPAIN
ETHIOPIA
FINLAND
FIJI
FALKLAND ISLANDS (MALVINAS)
MICRONESIA, FEDERATED STATES OF
FAROE ISLANDS
FRANCE
GABON
UNITED KINGDOM
GRENADA
GEORGIA
FRENCH GUIANA
GUERNSEY
GHANA
GIBRALTAR
GREENLAND
GAMBIA
GUINEA
GUADELOUPE
EQUATORIAL GUINEA
GREECE
SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS
GUATEMALA
GUAM
GUINEA-BISSAU
GUYANA
HONG KONG
HEARD ISLAND AND MCDONALD ISLANDS
HONDURAS
CROATIA
HAITI
HUNGARY
INDONESIA
IRELAND
ISRAEL
ISLE OF MAN
INDIA
BRITISH INDIAN OCEAN TERRITORY
IRAQ
IRAN, ISLAMIC REPUBLIC OF
ICELAND
ITALY
JERSEY
JAMAICA
JORDAN
JAPAN
KENYA
KYRGYZSTAN
CAMBODIA
KIRIBATI
COMOROS
SAINT KITTS AND NEVIS
KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF
KOREA, REPUBLIC OF
KUWAIT
CAYMAN ISLANDS
KAZAKHSTAN
LAO PEOPLE'S DEMOCRATIC REPUBLIC
LEBANON
SAINT LUCIA
LIECHTENSTEIN
SRI LANKA
LIBERIA
LESOTHO
LITHUANIA
LUXEMBOURG
LATVIA
LIBYA
MOROCCO
MONACO
MOLDOVA, REPUBLIC OF
MONTENEGRO
SAINT MARTIN (FRENCH PART)
MADAGASCAR
MARSHALL ISLANDS
MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF
MALI
MYANMAR
MONGOLIA
MACAO
NORTHERN MARIANA ISLANDS
MARTINIQUE
MAURITANIA
MONTSERRAT
MALTA
MAURITIUS
MALDIVES
MALAWI
MEXICO
MALAYSIA
MOZAMBIQUE
NAMIBIA
NEW CALEDONIA
NIGER
NORFOLK ISLAND
NIGERIA
NICARAGUA
NETHERLANDS
NORWAY
NEPAL
NAURU
NIUE
NEW ZEALAND
OMAN
PANAMA
PERU
FRENCH POLYNESIA
PAPUA NEW GUINEA
PHILIPPINES
PAKISTAN
POLAND
SAINT PIERRE AND MIQUELON
PITCAIRN
PUERTO RICO
PALESTINIAN, STATE OF
PORTUGAL
PALAU
PARAGUAY
QATAR
RÉUNION
ROMANIA
SERBIA
RUSSIAN FEDERATION
RWANDA
SAUDI ARABIA
SOLOMON ISLANDS
SEYCHELLES
SUDAN
SWEDEN
SINGAPORE
SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA
SLOVENIA
SVALBARD AND JAN MAYEN
SLOVAKIA
SIERRA LEONE
SAN MARINO
SENEGAL
SOMALIA
SURINAME
SOUTH SUDAN
SAO TOME AND PRINCIPE
EL SALVADOR
SINT MAARTEN (DUTCH PART)
SYRIAN ARAB REPUBLIC
SWAZILAND
TURKS AND CAICOS ISLANDS
CHAD
FRENCH SOUTHERN TERRITORIES
TOGO
THAILAND
TAJIKISTAN
TOKELAU
TIMOR-LESTE
TURKMENISTAN
TUNISIA
TONGA
TURKEY
TRINIDAD AND TOBAGO
TUVALU
TAIWAN, PROVINCE OF CHINA
TANZANIA, UNITED REPUBLIC OF
UKRAINE
UGANDA
UNITED STATES MINOR OUTLYING ISLANDS
UNITED STATES
URUGUAY
UZBEKISTAN
HOLY SEE (VATICAN CITY STATE)
SAINT VINCENT AND THE GRENADINES
VENEZUELA, BOLIVARIAN REPUBLIC OF
VIRGIN ISLANDS, BRITISH
VIRGIN ISLANDS, U.S.
VIET NAM
VANUATU
WALLIS AND FUTUNA
SAMOA
YEMEN
MAYOTTE
SOUTH AFRICA
ZAMBIA
ZIMBABWE





How can we help you?











Refresh



captcha:





 


Submit











Related Reports


Global Bacterial Vaginosis Drug Market Rport 2017

Jun-2017 | BisReport  | Pages : 134 | Code : MRS-152720 | 2350
                    
Global Bacterial Vaginosis Drug Market Report 2017 Full Report: 2350 Multi License (Section): 4700 Section Price: As below Page: 115 Chart and Figure: 124 Publisher: BisReport Delivery Time: 24 hour Contact: sales@bisreport.com Phone: +86-18701006088 With the slowdown in world economic growth, the Bacterial Vaginosis Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Bacterial Vaginosis Drug market size to maintain  Read more




Global Alzheimer's Disease Drug Market Rport 2017

Jun-2017 | BisReport  | Pages : 127 | Code : MRS-152719 | 2350
                    
Global Alzheimer’s Disease Drug Market Report 2017 Full Report: 2350 Multi License (Section): 4700 Section Price: As below Page: 115 Chart and Figure: 124 Publisher: BisReport Delivery Time: 24 hour Contact: sales@bisreport.com Phone: +86-18701006088 With the slowdown in world economic growth, the Alzheimer’s Disease Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Alzheimer’s Disease Drug market size to maintain  Read more




Global Protein Powder Detailed Analysis Report 2017-2022

Jul-2017 | Detailed Analysis Research | Pages : 153 | Code : MRS-152586 | 3250
                    
This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Protein Powder industry. This report splits Protein Powder market Price, Size, First Speciality, Second Speciality, Protein Powder Flavors, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022. This report focus Glob Read more




Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 63 | Code : MRS-152442 | 2000
                    
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape. Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amo Read more




Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 120 | Code : MRS-152441 | 2000
                    
Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pa Read more




Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 98 | Code : MRS-152440 | 2000
                    
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape. Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapi Read more




P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 39 | Code : MRS-152439 | 3500
                    
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2017 Summary According to the recently published report 'P2X Purinoceptor 7 - Pipeline Review, H2 2017'; P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated i Read more




Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 72 | Code : MRS-152438 | 3500
                    
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017 Summary Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia. Smoothened Homolog (Protein Gx Read more




Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 39 | Code : MRS-152437 | 3500
                    
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2017 Summary Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 o Read more




G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 34 | Code : MRS-152436 | 3500
                    
G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - Pipeline Review, H2 2017 Summary According to the recently published report 'G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2017'; G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) pipeline Target constitutes close to 8 molecules. Out of Read more








Payment Mode




Single User  | $(USD)1500








Multi User | $(USD)3000








Corporate User  | $(USD)4500













Latest Report


2017 Global Non-Slip Epoxy Glass Flake Paint Market Research Report


2017 Global Parking Sensors Market Research Report


2017 Global Nitrogen Oxide Sensor Market Research Report


2017 Global Nuclear Density Gauge Market Research Report


2017 Global Automotive Interior Materials Market Research Report

View More



Latest News


Global Chitosan Market Set for Rapid Growth, To Reach USD 4.74 Billion by 2021

Zion Market Research has published a new report titled Chitosan Market for Water Treatment, Biomed



Development of e-commerce to Reshape Global Mobile Hotspot Router Market

Mobile hotspot is a popular feature on smart phones that provide wireless internet access on many 



Global Carotenoids Market Is Expected To Reach Around USD 1.52 Billion in 2021

Zion Market Research has published a new report titled Carotenoids Market by Type (Astaxanthin, Be



Soaring Demand from Food & Beverages Industry to Act as Prime Driving for Ascorbic Acid Market, Reports Zion Market Research

Ascorbic acid is extensively available in nature, mostly rich in leafy vegetables and fresh fruits



Global Energy Management System (EMS) Market Is Set for a Rapid Growth and is Expected to Reach USD 63,161.5 million by 2021

Zion Market Research has published a new report titled Energy Management System Market (EMS) by So


View More














Single User | $(USD)1500
View Pricing 













Find Help

How to Order
Disclaimer 
FAQs
Return Policy
Sitemap



Our Company

About Us
Terms and Conditions
Privacy Policy



We accept the following payment methods






© 2016 - 2017 Market Research Store - Market Research Reports 









﻿



Cocrystal Pharma, Inc., Product Pipeline Review, 2016










































































    Agriculture and Animal Care 




Agriculture Equipment 

Agricultural Implements 
Combine Harvesters 
Rotavators 
Tillers 
Tractors 



Animal Care 

Animal Feed 
Animal Health 
Pet 



Crop Protection 

Agriculture Chemical 
Fertilizer 
Net Wrap 
Protected Cultivation 



Farming 

Field Crops 
Fishing 
Fruits and Vegetables 
Irrigation 
Plantations 



Seed 

Conventional Seed 
Hybrid Seed 






    Automotive, Transportation and Warehousing 




Automotive and Automotive Components 

Auto Components 
Automobiles 
Car Rental 
Hybrid Vehicles 
Lubricant 
Used Vehicles 



General Transportation 

Airlines Travel 
Aviation 
Railway 
Travel Intermediaries 



Logistics and Shipping 

Courier 
Packaging 
Transportation 
Value Added Services 
Warehousing 






    Banking Financial Services and Insurance 




Banking 

ATM 
Banknote 
Online Banking 
Retail Banking 



Financial Services 

Credit Rating 
Financial Advisory 
Investment Banking 
Payments 
Private Equity 
Remittance 
Stock Broking 
Vending Machines 
Wealth Management 



Insurance 

General Insurance 
Health Insurance 
Life Insurance 
Motor Insurance 
Reinsurance 



Loans and Advances 

Housing Loan 
Online Loans 
Vehicle Loan 






    Consumer Products and Retail 




Baby Care 

Baby Apparel and Footwear 
Baby Equipment 
Baby Food 
Baby Personal Care 
Maternity Products 



Consumer Electronics 

Audio Systems 
Camera 
Computers and Peripherals 
Large Appliances 
Lighting 
Mobile Phone and Accessories 



Consumer Services 

On-Demand Services 



Cosmetics and Personal Care 

Breath Fresheners 
Cosmeceuticals 
Disposable Consumer Products 
Eye care 
Flavors & Fragrance 
Hair Care 
Herbal Products 
Hygiene 
Nail Care 
Oral Care 
Personal Accessories 
Skin care 
Toiletries 



Home and Office Furnishings 

Air Purifier and Freshner 
Bathing 
Furniture 
Gardening 
Home Appliances 
Kitchenware 
Mattress 
Stationery 
Water Purifier 



Luxury Goods 

Artwork Products 
Cruises and Yachts 
Gems and Jewelry 
Luggage and bags 
Watch 



Sporting Equipments 

Bicycle 
Golf 



Textile, Apparel and Footwear 

Apparel and Footwear 
Apparel and Textile 
Athletic Apparel 
Innerwear 



Wholesale and Retail 

Departmental Stores 
Franchisee 
Grocery 
Store Cards 






    Defense and Security 




Defense 

Aerospace Products 
Air Force 
Aircraft Components 
Army 
Automation and Modernization 
Combat Vehicles 
MRO Services 
Navigational Instruments 
Navy 



Security Devices 

Access Control 
Cyber Security 
Fire Alarm 
Intrusion Alert 
IT Security 
Video Survelliance 



Weapon 

Ballistic Protection 
Military Ammunition 






    Education and Recruitment 




Education 

Corporate Education 
E Learning 
Higher Education 
Pre Primary 
Primary 
Secondary 
Teacher Training 
Test Preparation 
Vocational Education 



Recruitment 







    Energy and Utilities 




Clean Technology 

Biofuel 
Carbon Fibre 
Hydro 
Solar 
Waste Management 
Wind 



Gas 

LNG 
Natural Gas 
Shale Gas 



Oil 

Drilling and Exploration 
EOR 
Equipments and Services 
Fuel Dispenser 
Midstream 
Naphtha 
OCTG 
Oil Storage 
Petroleum Fuels 
Refining 
Upstream 



Power 

Electricity Generation and Transmission 
Inverter and UPS 
Nuclear 
Power Components 
Reservoir development 
Thermal 






    Food, Beverage and Tobacco 




Alcoholic Beverages 

Beer 
Cider 
Country Liquor 
IMFL 
Wine 



Dairy Products 

Butter 
Cheese 
Cream 
Dairy Products 
Milk 
Skim Milk Powder 
Soymilk 
Whey Powder 
Whole Milk Powder 
Yogurt and Ice Cream  



Food Services 

Catering 
Food Kiosks 
Quick Service Restaurant 



General Food 

Confectionary 
Cooking Oil 
Dry Fruits 
Flour Products 
Food Ingredients 
Frozen Food 
Gluten 
Organic Food 
Packaged food 
Processed Food 
Ready to Eat 
Spice 
Sugar 
Vending Machine 



Non Alcoholic Beverages 

Bottled Water 
Carbonated Soft Drinks 
Energy & Sports Drink 
Hot Beverage 
Iced Tea and Coffee 
Juice 



Tobacco Products 

Cigar 
Cigarette 
Hookah 
Smokeless Tobacco 






    Healthcare 




Diagnostics 

Diagnostic Lab 
In Vitro Diagnostics 
Sleep Apnea 



General Healthcare 

Biotechnology 
Healthcare IT 
Home Healthcare 
Hospitals and Clinics 
Old Age Homes 
Surgery 
Wellness 
Wound Care 



Medical Devices 

Aesthetic Laser 
Biopsy Devices 
Bone Growth Stimulators 
Cardiovascular 
Consumables 
Dental Equipment 
Diagnostic Imaging 
ENT 
Neurology Devices 
Orthopedic 



Pharmaceuticals 

Active Pharmaceutical Ingredient 
Blood Product 
CRAMS 
Diabetes 
Nutritional and Dietary Supplements 
Osteoporosis 
OTC Drug 
Pharmaceutical 
Pharmacy Stores 
Prescribed Drug 
Respiratory 
Vaccine 






    Manufacturing and Construction 




Construction Materials 

Aluminum 
Bricks and Blocks 
Cement 
Ceramics 
Electric Material 
Explosives 
Glass 
Hardware Materials 
Marbles and Granite 
Paper 
Refractory Materials 
Roofing Products 
Sanitaryware 
Steel 
Windows and Doors 
Wood 



Industrial Engineering 

Industrial Automation 
Interior Designing 



Infrastructure 

Construction 
Shipbuilding 



Machinery and Parts 

Construction Machinery 
Elevator and Escalator 
Home Automation 
Machinery Components 
Pipe and Valve 
Power Tools 
Pump 
Stamping Machine 
Tapes 



Other Manufacturing Activities 

MSME 



Real Estate 

Commercial 
Facility Management 
Green building 
Hotel 
Real Estate Consultancy 
Real Estate Investment Trust 
Residential 
Retail 






    Media and Entertainment 




Advertising 

Online Advertising 
Outdoor Advertising 



Films And Animation 

Music Stores & Instruments 
Online Music 
Theater 
Video Rental 



Gaming and Gambling 

Casino 
Online Gaming 
Theme Park 
Toys 
Video Game 



Information Services, Newspaper and Magazines 

Intelligence and Analytics 
Marketing 
Public 
Publishing 
Relations 



Tourism 

Medical Tourism 



TV, Radio and Broadcasting 

Cable 
IPTV 
Pay TV 






    Metal, Mining and Chemicals 




Chemicals 

Adhesive and Sealants 
Coating 
Fine Chemicals 
Organic Chemicals 
Paint 
Petrochemicals 
Plastics 
Polymer Materials 
Rubber 
Specialty Chemicals 



Metals & Minerals 

Ferrous Metals 
Non Ferrous Metals 



Mining 

Bauxite Mining 
Coal Mining 
Copper Mining 
Gold Mining 
Iron Ore Mining 
Other Mining 






    Public Sector and Administration 




Legal Services 




Public Services 




Religion 

funeral 
Wedding 






    Technology and Telecom 




IT and ITES 

E Commerce 
Embeded Systems 
Hosting 
ICT 
Process Outsourcing 
Semiconductor 
Software and Digital Content 
Technology Hardware 



Telecommunications and Networking 

Cloud Services 
Mobile Broadband 
MVAS 
Networking and Communication Equipment 
Smartphone 
Wireless 
Wireline 































 Advanced Search 




  




  CALL US NOW :
                  +1 855 298 4489(TOLL FREE)







  query [@] kenresearch.com









          0        



 







 Login
                


Email address



Password

Forgot the password ?







                      keep me logged-in 



 New here ? Join Us 












"Thanks for registering with us. Please login your your account."





Register











@@ Please be patient!! Your registration is in progress.
                            it will take few moment. 






Name*
:



Password*
:



Confirm Password*
:



Phone No.*
:



Email Id*
:
   Provide corporate/ academic email id only. In case of personal email id, provide Linkedin profile link in the company address 


Company Name
:
 		   Company Name and Address is required for invoicing process. 






Company Address*
:
    Company Name and Address is required for invoicing process. 


State*
:
 


Country*
:

Select
Afghanistan
Algeria
Argentina
Australia
Austria
Bahamas
Bangladesh
Barbados
Belgium
Belize
Bermuda
Bolivia
Brazil
Brunei Darussalam 
Bulgaria
Canada
Czech Republic
Chile 
China 
Colombia
Costa Rica
Croatia
Denmark
Dominican Republic
Ecuador
Egypt
Estonia
England
Finland
France
Germany
Guatemala
Greece
Honduras
Hong Kong
Hungary
Iceland
Ireland
India
Indonesia
Iran
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lebanon
Liechtenstein
Lithuania
Luxembourg
Malaysia
Maldives
Malta
Mexico
Monaco
Morocco
Nepal
Netherlands
New Zealand
Norway 
Pakistan
Panama
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Romania
Russia
Saudi Arabia
Scotland
Singapore
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Thailand
Turkey
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Venezuela
Vietnam
Yugoslavia
Wales
Others




Pin Code
:




Validation:*


   If validation code does not match, please refresh the page.



                                Subscribe for the Newsletter


 
 






























Forgot password ? 













Email Id*
:



 
 




























Forgot password ? 













Email Id*
:



 
 





























 About Us
 Services
 Categories
 News
 Contact Us







You Are Here
>
Home
>


        Healthcare        
>

                Pharmaceuticals













select a format



 












Single User License



USD 1500
INR 96210














Site License



USD 3000
INR 192420














Corporate User License



USD 4500
INR 288630
























Alternatively






Request a quote


"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."







request a Quote












Name*
:



Designation*
:



Email*
:



Phone No.*
:



Company Name*
:



Company URL*
:



Current Budget
:



Security code
:

   
If validation Code Does Not Match Please Refresh The Page.


Report Title
:
Cocrystal Pharma, Inc.-Product Pipeline Review-2016




Quote Request for License Type




License Type
 
License Rights
Price


Single User License
:-
Electronic PDF for Single User; No Print; No Copy; only Internal Use
USD 1500






Site License
:-
Electronic PDF for Site Use across Authorised Users in a Single Location with Print and Copy Rights; only Internal Use
USD 3000




Enterprise Wide License
:-
Electronic PDF for Enterprise wide across Multiple Locations with Print and Copy Rights; only Internal Use
USD 4500






 


















Request a Customized research

"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."








request a customized research












Name*
:



Designation*
:



Email*
:



Phone No.*
:



Company Name*
:



Company URL*
:



Current Budget
:



Report Title
:
Cocrystal Pharma, Inc.-Product Pipeline Review-2016


Requirement
:





Timeline ( In Working Days )
:



Security code
:

   
If validation Code Does Not Match Please Refresh The Page.




Quote Request for License Type




License Type
 
License Rights
Price


Single User License
:-
Electronic PDF for Single User; No Print; No Copy; only Internal Use
USD 1500






Site License
:-
Electronic PDF for Site Use across Authorised Users in a Single Location with Print and Copy Rights; only Internal Use
USD 3000




Enterprise Wide License
:-
Electronic PDF for Enterprise wide across Multiple Locations with Print and Copy Rights; only Internal Use
USD 4500






 


















Request for Sample Report


"Thank you for submitting the form. The concerned team will will get back to you within next 24 hours."
"Thank you for downloading the sample report."







request For sample Report












Report Title
:
Cocrystal Pharma, Inc.-Product Pipeline Review-2016


Name*
:



Designation*
:



Email*
:



Phone No.*
:



Company Name*
:



Company URL*
:



Security code
:

   
If validation Code Does Not Match Please Refresh The Page.

Requirement
:






 























NEWSLETTER BY CATEGORY
FOR REGULAR UPDATES ON OUR LATEST RESEARCH REPORTS

Subscribe Newsletter





 

  







Interested Areas




Agriculture and Animal Care



Automotive, Transportation and Warehousing



Banking Financial Services and Insurance



Consumer Products and Retail



Defense and Security



Education and Recruitment



Energy and Utilities



Food, Beverage and Tobacco



Healthcare



Manufacturing and Construction



Media and Entertainment



Metal, Mining and Chemicals



Public Sector and Administration



Technology and Telecom












FAQ


Clientele
















Recent Viewed Reports









Why Ken Reasearch?




  









 
 Compare Reports to make Purchase Decision 
 
 Prepaid Account 
                                to Get 
                                you Valuable Discount
 
 customized research 
                                for business study
 
 Purchase 
                                the section 
                                to save on
                                next
                                research











Testimonials




This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"
I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"
While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. 
We hope to see more of such well researched reports. 
All the best & keep it up. 
... "Prashant Bhagwat,General Manager, Mahindra"
We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"
The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


















Cocrystal Pharma, Inc.-Product Pipeline Review-2016







Products Id :- GMDHC08075CDB
|
Pages: 44
|
June 2016
|
Region: 
                             Global
|






Global Markets Direct
|
Market Research Report









   Request for Sample Report














Use KENCB10
KENCB10 - Avail a discount of 10% and cash back of 10% on all publications. Applicable on all licenses. 
Not Applicable on Ken Research Publications
Limited Time Period Offer
T&C apply
*T&C Apply

        • Promo code can be used 1 time per user 
        • Cash Back will be credited with in 24 hours of the transaction into user's Ken Wallet. In case of any issues please contact query@kenresearch.com.
        • We reserve the right to cancel any or all offers at our discretion without any aforementioned notice.
        • The money would remain in Ken Wallet and can be used to purchase any other publication available on the company's website.
        • Discount and cashback code will not be applicable on section purchase.






 < 
Previous


 > 
Next











Summary
Scope
List of Figure
List of table
Licence Rights
Companies
Products






Executive Summary
Cocrystal Pharma, Inc.-Product Pipeline Review-2016
Summary
Global Markets Direct's, 'Cocrystal Pharma, Inc.-Product Pipeline Review-2016', provides an overview of the Cocrystal Pharma, Inc.'s pharmaceutical research and development focus. 
The report provides comprehensive information on the therapeutics under development by Cocrystal Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the pipeline therapeutic landscape of Cocrystal Pharma, Inc.
The report provides overview of Cocrystal Pharma, Inc. including its business description, key facts, and locations and subsidiaries
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
The report assesses Cocrystal Pharma, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
The report features Cocrystal Pharma, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons To Buy
Evaluate Cocrystal Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
Identify and understand important and diverse types of therapeutics under development for Cocrystal Pharma, Inc.
Identify potential new clients or partners in the target demographic
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Cocrystal Pharma, Inc.'s pipeline depth and focus of pipeline therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  Contact Us:
 
Ken Research 
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com 
+91-9015378249
www.kenresearch.com






 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Cocrystal Pharma, Inc. Snapshot 6
Cocrystal Pharma, Inc. Overview 6
Key Information 6
Key Facts 6
Cocrystal Pharma, Inc.-Research and Development Overview 7
Key Therapeutic Areas 7
Cocrystal Pharma, Inc.-Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products-Monotherapy 11
Pipeline Products-Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Cocrystal Pharma, Inc.-Pipeline Products Glance 14
Cocrystal Pharma, Inc.-Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Cocrystal Pharma, Inc.-Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Cocrystal Pharma, Inc.-Drug Profiles 17
CC-31244 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CC-1845 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CC-2068 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CC-2069 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CDI-244 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy for Hepatitis B and Human Papilloma Virus Infections 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CC-31326 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RS-1137 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
RS-1142 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RS-1145 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RS-930 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RS-961 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Hepatitis C 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit PB2 for Influenza 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Norovirus Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cocrystal Pharma, Inc.-Pipeline Analysis 34
Cocrystal Pharma, Inc.-Pipeline Products by Target 34
Cocrystal Pharma, Inc.-Pipeline Products by Route of Administration 35
Cocrystal Pharma, Inc.-Pipeline Products by Molecule Type 36
Cocrystal Pharma, Inc.-Pipeline Products by Mechanism of Action 37
Cocrystal Pharma, Inc.-Recent Pipeline Updates 38
Cocrystal Pharma, Inc.-Dormant Projects 41
Cocrystal Pharma, Inc.-Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44






List of Figures
Cocrystal Pharma, Inc.-Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc.-Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc.-Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc.-Pipeline by Target, 2016 34
Cocrystal Pharma, Inc.-Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc.-Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc.-Pipeline Products by Mechanism of Action, 2016 37






List of Tables
Cocrystal Pharma, Inc., Key Information 6
Cocrystal Pharma, Inc., Key Facts 6
Cocrystal Pharma, Inc.-Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc.-Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc.-Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc.-Out-Licensed Products in Pipeline, 2016 12
Cocrystal Pharma, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Cocrystal Pharma, Inc.-Phase I, 2016 14
Cocrystal Pharma, Inc.-Preclinical, 2016 15
Cocrystal Pharma, Inc.-Discovery, 2016 16
Cocrystal Pharma, Inc.-Pipeline by Target, 2016 34
Cocrystal Pharma, Inc.-Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc.-Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc.-Pipeline Products by Mechanism of Action, 2016 37
Cocrystal Pharma, Inc.-Recent Pipeline Updates, 2016 38
Cocrystal Pharma, Inc.-Dormant Developmental Projects,2016 41
Cocrystal Pharma, Inc., Other Locations 42






Single User License:
                        Report can be used by individual purchaser only
Site License:
                        Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License: 
                        Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company








To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com  
 









3SBio Inc.
Amgen Inc.
Eisai Co., Ltd.
Intas Pharmaceuticals Ltd.
Novartis AG
Shionogi & Co., Ltd.
STATegics, Inc.






Current R&D Portfolio of Cocrystal Pharma, Inc.; Cocrystal Pharma, Inc.-Key Therapeutics; Cocrystal Pharma, Inc.-Pipeline Overview and Promising Molecules; Cocrystal Pharma, Inc.-News; Cocrystal Pharma, Inc.-Latest Updates; Cocrystal Pharma, Inc.-Pipeline; Cocrystal Pharma, Inc.-Discontinued/Dormant Projects



















Related Products in vertical




Vietnam Nutraceuticals Market Outlook to 2021 - Rising Demand For Infant Products and Probiotic Supplements to Foster Future Growth    
              Ken Research |   Page 71 | July 2017 Read More 







Thailand Nutraceuticals Market Outlook to 2021 - Rising Trust over Herbal Ingredients with Increasing use of Ginseng in Functional Foods to Foster Future Growth    
              Ken Research |   Page 80 | July 2017 Read More 







Korea Nutraceuticals Market Outlook to 2021 - Rising Trust over Herbal Ingredients with Increasing use of Ginseng in Functional Foods to Foster Future Growth   
              Ken Research |   Page 83 | July 2017 Read More 











Other reports by publisher




Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)-Pipeline Review, H1 2017 
              Global Markets Direct |   Page 35 | May 2017 Read More 







Osteonecrosis-Pipeline Review, H1 2017 
              Global Markets Direct |   Page 34 | May 2017 Read More 







Type 2 Diabetes-Pipeline Review, H1 2017 
              Global Markets Direct |   Page 1100 | May 2017 Read More 


















Company


Home
About Us
Services
Categories
News
Contact Us
Careers
RSS Feeds






Quick links


Blog
Industry Reports
Equity Research Reports
Country Research Reports
Deal Directory
Publishers
Upcoming Publication 
Latest Publications






Other Links


Discounted Reports
Discount Coupons
Media Releases
Testimonial
Terms & Conditions
Privacy Policy
Disclaimer
FAQ's
SITE MAP






Contact Us


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49 
	 &nbsp&nbsp&nbsp&nbsp&nbspGurgaon, Haryana  - 122001, India 
 +91 1244230204




Follow us




























Wish to Know more
About Us







download
Company Brochure












For Further Enquiry
careers







apply for job





"Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."




Come On! We Need You

Make a start to an incredible career









Applicant Name*







Job function*




Job function
Market Research Associate
Market research analyst
SEO Executive
Content Writer
Web Designer
Hr Specialist




Total Experience






Year




Year
0
1
2
3
4
5
6
7
8
9
10








Months




Months
Year
0
1
2
3
4
5
6
7
8
9
10
11
12






Skills






Email ID *












Notice Period






Current CTC & Expected CTC





CTC(Monthly)









Expected CTC(monthly)








Phone Number*









Validation:


     If validation code does not match, please refresh the page.





 







 























Know how We Roll
Our services







Engage with Us
query [@] kenresearch.com







"Thanks for submitting the form. Please refer to the attached brochure."



Company Brochure



Name*

Email*

Company Name*

Select Country*

Select
Afghanistan
Algeria
Argentina
Australia
Austria
Bahamas
Bangladesh
Barbados
Belgium
Belize
Bermuda
Bolivia
Brazil
Brunei Darussalam 
Bulgaria
Canada
Czech Republic
Chile 
China 
Colombia
Costa Rica
Croatia
Denmark
Dominican Republic
Ecuador
Egypt
Estonia
England
Finland
France
Germany
Guatemala
Greece
Honduras
Hong Kong
Hungary
Iceland
Ireland
India
Indonesia
Iran
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lebanon
Liechtenstein
Lithuania
Luxembourg
Malaysia
Maldives
Malta
Mexico
Monaco
Morocco
Nepal
Netherlands
New Zealand
Norway 
Pakistan
Panama
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Romania
Russia
Saudi Arabia
Scotland
Singapore
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Thailand
Turkey
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Venezuela
Vietnam
Yugoslavia
Wales
Others


Phone No.*

Validation*

    If validation code does not match, please refresh the page.













"Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"



Engage with Us



Name*

Designation*

Email*

Phone No.*

Company Name*

Company URL*

Select Country*

Select
Afghanistan
Algeria
Argentina
Australia
Austria
Bahamas
Bangladesh
Barbados
Belgium
Belize
Bermuda
Bolivia
Brazil
Brunei Darussalam 
Bulgaria
Canada
Czech Republic
Chile 
China 
Colombia
Costa Rica
Croatia
Denmark
Dominican Republic
Ecuador
Egypt
Estonia
England
Finland
France
Germany
Guatemala
Greece
Honduras
Hong Kong
Hungary
Iceland
Ireland
India
Indonesia
Iran
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lebanon
Liechtenstein
Lithuania
Luxembourg
Malaysia
Maldives
Malta
Mexico
Monaco
Morocco
Nepal
Netherlands
New Zealand
Norway 
Pakistan
Panama
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Romania
Russia
Saudi Arabia
Scotland
Singapore
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Thailand
Turkey
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Venezuela
Vietnam
Yugoslavia
Wales
Others

Requirements/ Comments*

Validation*
    If validation code does not match, please refresh the page.























Net Wrap 
/  Store Cards 
/  Dry Fruits 
/  On-Demand Services 
/  Online Music 
/  Bicycle 
/  Personal Accessories 
/  Herbal Products 
/  Food Kiosks 
/  Upstream 
/  Bricks and Blocks 
/  Stamping Machine 
/  Hookah 
/  Fishing 
/  Breath Fresheners 
/  Respiratory 
/  Neurology Devices 
/  Petrochemicals 
/  Power Tools 
/  Reservoir development 
/  Petroleum Fuels 
/  Audio Systems 
/  Specialty Chemicals 
/  Polymer Materials 
/  Process Outsourcing 
/  Intelligence and Analytics 
/  Artwork Products 
/  Processed Food 
/  MRO Services 
/  Aerospace Products 
/  Bone Growth Stimulators 
/  Midstream 
/  Baby Equipment 
/  Rubber 
/  Equipments and Services 
/  Airlines Travel 
/  Electricity Generation and Transmission 
/  Fuel Dispenser 
/  Refining 
/  Biopsy Devices 























Compare

















My Shortlist 






Compare
My Shortlist












 



























